|
| ADR REPORT |
|
| Year : 2013 | Volume
: 59
| Issue : 4 | Page : 306-308 |
Fatal acute pancreatitis in a patient with visceral leishmaniasis during miltefosine treatment
K Pandey1, D Singh2, CS Lal3, VNR Das1, P Das2
1 Department of Clinical Medicine, Rajendra Memorial Research Institute of Medical Sciences, Indian Council of Medical Research, Agamkuan, Patna, Bihar, India
2 Department of Molecular Biology, Rajendra Memorial Research Institute of Medical Sciences, Indian Council of Medical Research, Agamkuan, Patna, Bihar, India
3 Department of Clinical Biochemistry, Rajendra Memorial Research Institute of Medical Sciences, Indian Council of Medical Research, Agamkuan, Patna, Bihar, India
Correspondence Address:
K Pandey
Department of Clinical Medicine, Rajendra Memorial Research Institute of Medical Sciences, Indian Council of Medical Research, Agamkuan, Patna, Bihar
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0022-3859.123161
Pancreatitis is a known side effect of the once commonly used drug, sodium stibogluconate, for treatment of visceral leishmaniasis (VL). In India, miltefosine has recently been introduced as the first-line drug. Its side effects include loose motions, vomiting, and teratogenicity. We report here a case of a 41-year-old parasitologically confirmed male case of VL, who developed acute pancreatitis during treatment with miltefosine. On the 13 th day of treatment, he presented with abdominal pain and vomiting. The biochemical, hematological, and radiological features were suggestive of acute pancreatitis. The patient was put on conservative treatment for pancreatitis at the specialized center but succumbed to renal failure and septicaemia.
[FULL TEXT] [PDF]*
|
